8.73
0.04 (0.46%)
| Previous Close | 8.69 |
| Volume | 441,007 |
| Price / Earnings (Forward) | 7.26 |
| Price / Sales | 0.680 |
| Price / Book | 0.900 |
| 52 Weeks Range | |
| TTM Dividend Yield | 1.08% |
| Profit Margin | 2.65% |
| Operating Margin (TTM) | 16.42% |
| Diluted EPS (TTM) | 0.270 |
| Quarterly Revenue Growth (YOY) | 9.80% |
| Quarterly Earnings Growth (YOY) | 178.80% |
| Total Debt/Equity (MRQ) | 121.14% |
| Current Ratio (MRQ) | 2.60 |
| Operating Cash Flow (TTM) | 1.20 B |
| Levered Free Cash Flow (TTM) | 2.26 B |
| Return on Assets (TTM) | 3.99% |
| Return on Equity (TTM) | 3.45% |
AIStockmoo Score
| Value 30% | 0.7 |
| Cheaper than its usual valuation. Counted for less, as its earnings have been uneven. info | |
| Earns below its cost of capital. Returns on capital falling. info | |
| High debt. Weak profitability. Ample short-term liquidity. Positive cash flow. info | |
| From our AI Insight report's view of expected return against risk. info | NA |
| Relative Valuation info | NA |
| Implied Growth info | NA |
| Holdings' Value info | NA |
| Risk Premium info | NA |
| Market Valuation info | NA |
| Timing 30% | 1.4 |
| Downtrend over the past year. Somewhat below its 52-week high. info | |
| In an uptrend: the price is above its moving averages, and they are rising. It is close to them. Volume is heavier on up days. info | |
| From our AI technical analysis of the chart. info | NA |
| Candle Patterns info | NA |
| Sentiment 20% | 0.0 |
| No recent price targets, so based on how targets have been revised. info | |
| Holdings' Sentiment info | NA |
| News Mood info | NA |
| Smart Money 20% | 1.1 |
| Institutions net +2.76% of shares in their latest 13F filings: 86 holders increased, 72 decreased (quarter to 30 Sep 2026). info | |
| Short interest +75.0% from 31 Aug to 30 Oct 2026, 8.1 days to cover (FINRA). info | |
| Insider Activity info | NA |
| Market and sector conditions are neutral. | |
| Market environment cautious. info | |
| Sector outperforming the market. | |
| The pillars agree, so the score is strengthened. | |
| Not in score | |
| Earnings per share have gone up and down. Earnings have been uneven. info | |
| Above its medium-term trend line. info | |
| Price is high against its 52-week average. Down over 5 years. info | |
| Short-term momentum rising. info | |
| Price is near resistance. Levels trending up. info | |
| Final Score | 1.07 |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - General (US) | Mixed | Bullish |
| Drug Manufacturers - General (Global) | Mixed | Bullish | |
| Stock | Grifols, S.A. | Mixed | Bearish |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B | Score |
|---|---|---|---|---|---|
| GRFS | - | 1.08% | - | 0.900 | 1.1 |
| BIIB | - | - | - | 1.98 | 0.8 |
| SNY | 112 B | 5.21% | 23.14 | 1.37 | 0.3 |
| AMGN | 236 B | 2.28% | 25.25 | 16.73 | 1.0 |
| GILD | 206 B | 1.95% | - | 16.08 | 0.6 |
| MIRA | 15 M | - | 36.83 | 3.72 | -1.0 |
Select this tab to load the latest available analysis.
|
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Investment Style | Mid Value |
| % Held by Institutions | 58.60% |
No data within this time range.
No data within this time range.
Institutions
Institutional ownership: 56.23%
| Positions | Holders | Shares |
|---|---|---|
| Increased | 86 | 10,179,899 |
| Decreased | 72 | 6,444,970 |
| New | 18 | 3,772,224 |
| Sold out | 18 | 312,746 |
SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.
Short Interest
| Settlement | Shares | Days to cover |
|---|---|---|
| 30 Oct 2026 | 5,978,971 | 8.1 |
| 15 Oct 2026 | 6,990,415 | 15.9 |
| 30 Sep 2026 | 7,001,241 | 8.7 |
| 15 Sep 2026 | 3,414,455 | 8.8 |
| 31 Aug 2026 | 3,417,230 | 8.4 |
| 14 Aug 2026 | 3,516,392 | 9.8 |
FINRA short interest via Nasdaq, reported twice a month.
| Date | Type | Details |
|---|---|---|
| 03 Nov 2026 | Yahoo Finance |
Grifols (BME:GRF) Stock Price Trails Q3 Results As Debt Questions Linger
Grifols just printed its Q3 2026 report and the story is not the share price. The stock closed at €11.23 on 3 November, well below a stated cash flow value estimate of €36.08, even as the plasma giant delivered adjusted EBITDA of €538m with a 26.4% margin and net leverage of about 3.98x. This is a… |
| 03 Nov 2026 | Yahoo Finance |
Grifols Beats Q3 Revenue Forecasts as Immunoglobulin Demand Supports Profit Growth
Grifols (NASDAQ:GRFS) reported stronger-than-expected third-quarter revenue, supported by continued growth in its Biopharma division and rising demand for immunoglobulin products. The Spanish pharmaceutical company also delivered higher profitability, improved cash generation and a reduction in… |
| 03 Nov 2026 | Yahoo Finance |
Grifols SA (GRFS) Q3 2026 Earnings Call Highlights: Biopharma Growth Accelerates as Margin ...
Grifols SA (GRFS) posted 8.4% constant-currency revenue growth and a 26.4% adjusted EBITDA margin in Q3 2026, while navigating China albumin headwinds and Diagnostics declines. |
| 02 Nov 2026 | Yahoo Finance |
Grifols (GRFS) Q3 2026 Earnings Call Transcript
Biopharma revenue grew 10.3% as net leverage fell below 4.0x. |
| 02 Nov 2026 | Yahoo Finance |
Grifols Q3 Earnings Call Highlights
Grifols (NASDAQ:GRFS) reported third-quarter 2026 results marked by revenue growth, expanding profitability, stronger free cash flow and lower leverage, while management reiterated its full-year financial targets despite continued weakness in China’s albumin market. Chief Executive Officer Nacho Ab… |
| 02 Nov 2026 | Yahoo Finance |
Grifols Q3 revenue exceeds estimates as immunoglobulin sales drive growth
Investing.com -- Grifols reported third-quarter revenue above expectations on Monday, driven by growth in its Biopharma business, and confirmed its full-year guidance. The company’s U.S.-listed shares closed 5% higher in the Monday session but slipped 1.4% in premarket trading Tuesday. |
| 02 Nov 2026 | Yahoo Finance |
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading
European equities traded in the US as American depositary receipts began the week tracking higher la… |
| 30 Oct 2026 | Yahoo Finance |
European Equities Traded in the US as American Depositary Receipts Fall in Friday Trading
European equities traded in the US as American depositary receipts were down 0.59% to 1,896.05 on th… |
| 27 Oct 2026 | Yahoo Finance |
Grifols (BME:GRF) Stock Still Looks Cheap Based On Current Earnings
Grifols has seen sharp swings over recent years, and that kind of ride naturally raises a blunt question for you as an investor: Does the current share price line up with what the business is actually earning today? The stock has fallen 44.9% over the past 5 years, which puts the spotlight firmly… |
| 26 Oct 2026 | Yahoo Finance |
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading
European equities traded in the US as American depositary receipts started the week higher late Mond… |
| 23 Oct 2026 | Yahoo Finance |
Plasma Demand Supports Grifols, S.A.’s (GRFS) Path Back to Financial Strength
White Falcon’s Q3 2026 letter reports 2.7% quarterly and 4.6% year-to-date net returns. The letter can be downloaded here. Management attributes the underperformance mainly to a sharp September pullback, rising interest rates, and zero energy exposure. The portfolio remains concentrated in… |
| 14 Oct 2026 | Yahoo Finance |
European Equities Traded in the US as American Depositary Receipts Edge Lower in Wednesday Trading
European equities traded in the US as American depositary receipts were marginally lower late Wednes… |
| 11 Oct 2026 | Yahoo Finance |
Can Ambu (CPSE:AMBU B) Look Undervalued As Board Changes Put Governance In Focus?
Boardroom shift puts governance in focus Ambu (CPSE:AMBU B) has drawn attention after appointing Jose Ignacio "Nacho" Abia as an observer to its Board of Directors, bringing experience from Grifols and more than two decades at Olympus. Recent trading has turned more upbeat for Ambu, with a 1-day… |
| 07 Oct 2026 | Yahoo Finance |
Are Options Traders Betting on a Big Move in Grifols Stock?
Investors need to pay close attention to GRFS stock based on the movements in the options market lately. |
| 26 Sep 2026 | Yahoo Finance |
Grifols (BME:GRF) Stock May Be Below Fair Value On Earnings
Grifols has seen a long share price slide in recent years, which naturally puts the focus on one question for investors who still follow the stock. Is the current price tag properly supported by the earnings the business is generating today. Over the past 5 years the share price has fallen 54%… |
| 25 Sep 2026 | Yahoo Finance |
European Equities Traded in the US as American Depositary Receipts Edge Higher in Friday Trading; Down for Week
European equities traded in the US as American depositary receipts were tracking modestly higher lat… |
| Show more | ||
| TTM Dividend Yield | 1.08% |
| 5Y Average Dividend Yield | 1.18% |
| Expected Next Dividend Payment | Jul 2027 |
| Ex Date | Announcement Date | Payment Date | Details |
|---|---|---|---|
| 03 Dec 2026 | 03 Nov 2026 | 11 Jan 2027 | 0.168574 Cash |
| 02 Jul 2026 | 19 Jun 2026 | 09 Jul 2026 | 0.094458 Cash |
| 12 Aug 2025 | 30 Jul 2025 | 20 Aug 2025 | 0.173385 Cash |
| 03 Jun 2021 | 21 May 2021 | 14 Jun 2021 | 0.456586 Cash |
| 30 Oct 2020 | 16 Oct 2020 | 09 Nov 2020 | 0.201439 Cash |
| 02 Dec 2019 | 31 Oct 2019 | 11 Dec 2019 | 0.221872 Cash |
| 07 Jun 2019 | 29 May 2019 | 18 Jun 2019 | 0.175638 Cash |
| 30 Nov 2018 | 07 Nov 2018 | 11 Dec 2018 | 0.22789 Cash |
| 01 Jun 2018 | 25 May 2018 | 12 Jun 2018 | 0.250975 Cash |
| 01 Dec 2017 | - | 12 Dec 2017 | 0.212979 Cash |
| 30 May 2017 | - | 08 Jun 2017 | 0.163528 Cash |
| 05 Dec 2016 | - | 14 Dec 2016 | 0.193644 Cash |
| 02 Jun 2016 | - | 15 Jun 2016 | 0.162059 Cash |
| 10 Dec 2015 | - | 17 Dec 2015 | 0.384765 Cash |
| 08 Jun 2015 | - | 15 Jun 2015 | 0.341846 Cash |
| 04 Dec 2014 | - | 12 Dec 2014 | 0.312792 Cash |
| 05 Jun 2013 | 24 May 2013 | 13 Jun 2013 | 0.258668 Cash |
| Show more | |||
Annual Dividend Yield
| Year | Annual Dividend ($) | Frequency/Year | Yield % |
|---|---|---|---|
| 2026 | 0.094 | 1 | 1.08 |
| 2025 | 0.173 | 1 | 1.85 |
| 2021 | 0.457 | 1 | 4.07 |
| 2020 | 0.201 | 1 | 1.09 |
| 2019 | 0.398 | 2 | 1.71 |
| 2018 | 0.479 | 2 | 2.61 |
| 2017 | 0.377 | 2 | 1.64 |
| 2016 | 0.356 | 2 | 2.21 |
| 2015 | 0.727 | 2 | 4.49 |
| 2014 | 0.313 | 1 | 1.84 |
| 2013 | 0.259 | 1 | 1.43 |
| Show more | |||
Technical Setup Medium
AI Technical Analysis
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |